BBOT — Bridgebio Oncology Therapeutics Share News
0.000.00%
Last trade - 00:00- $213.26m
- -$12.45m
Brief: Bridgebio Oncology Therapeutics - May Offer Up To $500 Million In Securities - SEC Filing
Brief: Bridgebio Oncology Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule
BridgeBio Oncology Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview
Brief: Bbot Reports First Quarter 2026 Financial Results And Update On Corporate Progress
Brief: Bridgebio Oncology Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: BBOT Granted US FDA Fast Track Designation For BBO-11818 For Treatment of Adult Patients With Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma
Brief: Bridgebio Oncology Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP-KKR, Sirius XM, Workday
Brief: Bbot Announces Poster Presentations At The 2025 Aacr-Nci-Eortc International Conference
Brief: Helix Acquisition Corp. II Retains More Than 60% Of Trust Account